Pathophysiology of myasthenia gravis with antibodies to the acetylcholine receptor, muscle-specific kinase and low-density lipoprotein receptor-related protein 4

Autoimmunity Reviews

Volumn 12, Issue 9, 2013, Pages 918-923

  Verschuuren, Jan J G M ^a   Huijbers, Maartje G ^a   Plomp, Jaap J ^a   Niks, Erik H ^a   Molenaar, Peter C ^b   Martinez Martinez, Pilar ^b   Gomez, Alejandro M ^b   De Baets, Marc H ^b   Losen, Mario ^b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

AChR; Lrp4; MuSK; Myasthenia gravis; Neuromuscular junction

Indexed keywords

ANTIBODY; CHOLINERGIC RECEPTOR ANTIBODY; CHOLINESTERASE INHIBITOR; COMPLEMENT; HLA ANTIGEN CLASS 2; LIGAND; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 4 ANTIBODY; MUSCLE SPECIFIC KINASE ANTIBODY; RITUXIMAB; UNCLASSIFIED DRUG;

ANTIBODY AFFINITY; BINDING SITE; COMPLEMENT ACTIVATION; CONFORMATIONAL TRANSITION; GENE FREQUENCY; HUMAN; LIGAND BINDING; MYASTHENIA GRAVIS; NONHUMAN; PATHOPHYSIOLOGY; PEMPHIGUS FOLIACEUS; PEMPHIGUS VULGARIS; PROTEIN CROSS LINKING; REVIEW;

ANIMALS; AUTOANTIBODIES; COMPLEMENT ACTIVATION; HUMANS; LDL-RECEPTOR RELATED PROTEINS; MYASTHENIA GRAVIS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, CHOLINERGIC;

EID: 84879182892     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2013.03.001     Document Type: Review

References (118)

1. Zisimopoulou P., Brenner T., Trakas N., Tzartos S.J. Serological diagnostics in myasthenia gravis based on novel assays and recently identified antigens. Autoimmun Rev 2013, 12(9):924-930. (this issue).
2. Mori S., Shigemoto K. Mechanisms associated with the pathogenicity of antibodies against muscle-specific kinase in myasthenia gravis. Autoimmun Rev 2013, 12(9):912-917. (this issue).
3. Evoli A., Padua L. Diagnosis and therapy of myasthenia gravis with antibodies to muscle-specific kinase. Autoimmun Rev 2013, 12(9):931-935. (this issue).
4. Engel A.G. Congenital myasthenic syndromes in 2012. Curr Neurol Neurosci Rep 2012, 12:92-101.
5. Ramanujam R., Pirskanen R., Ramanujam S., Hammarstrom L. Utilizing twins concordance rates to infer the predisposition to myasthenia gravis. Twin Res Hum Genet 2011, 14:129-136.
6. Lavrnic D., Nikolic A., De Baets M., Verschuuren J., Verduyn W., Losen M., et al. Familial occurrence of autoimmune myasthenia gravis with different antibody specificity. Neurology 2008, 70:2011-2013.
7. Evoli A., Batocchi A.P., Zelano G., Uncini A., Palmisani M.T., Tonali P. Familial autoimmune myasthenia gravis: report of four families. J Neurol Neurosurg Psychiatry 1995, 58:729-731.
8. Provenzano C., Arancio O., Evoli A., Rocca B., Bartoccioni E., de Grandis D., et al. Familial autoimmune myasthenia gravis with different pathogenetic antibodies. J Neurol Neurosurg Psychiatry 1988, 51:1228-1230.
9. Bergoffen J., Zmijewski C.M., Fischbeck K.H. Familial autoimmune myasthenia gravis. Neurology 1994, 44:551-554.
10. Tüzün E., Christadoss P. Complement Associated Pathogenic Mechanisms in Myasthenia Gravis. Autoimmun Rev 2013, 12(9):904-911. (this issue).
11. Gomez A.M., Van Den Broeck J., Vrolix K., Janssen S.P., Lemmens M.A., Van Der Esch E., et al. Antibody effector mechanisms in myasthenia gravis - pathogenesis at the neuromuscular junction. Autoimmunity 2010, 43:353-370.
12. Shiono H., Wong Y.L., Matthews I., Liu J.L., Zhang W., Sims G., et al. Spontaneous production of anti-IFN-alpha and anti-IL-12 autoantibodies by thymoma cells from myasthenia gravis patients suggests autoimmunization in the tumor. Int Immunol 2003, 15:903-913.
13. Le Panse R., Bismuth J., Cizeron-Clairac G., Weiss J.M., Cufi P., Dartevelle P., et al. Thymic remodeling associated with hyperplasia in myasthenia gravis. Autoimmunity 2010, 43:401-412.
14. Alpert L.I., Papatestas A., Kark A., Osserman R.S., Osserman K. A histologic reappraisal of the thymus in myasthenia gravis. A correlative study of thymic pathology and response to thymectomy. Arch Pathol 1971, 91:55-61.
15. Myking A., Skeie G.O., Varhaug J.E., Andersen K.S., Gilhus N.E., Aarli J.A. The histomorphology of the thymus in late onset, non-thymoma myasthenia gravis. Eur J Neurol 1998, 5:401-405.
16. Maniaol A.H., Elsais A., Lorentzen A.R., Owe J.F., Viken M.K., Saether H., et al. Late onset myasthenia gravis is associated with HLA DRB1*15:01 in the Norwegian population. PLoS One 2012, 7:e36603.
17. Cavalcante P., Cufi P., Mantegazza R., Berrih-Aknin S., Bernasconi P., Le Panse R. Etiology of myasthenia gravis: innate immunity signature in pathological thymus. Autoimmun Rev 2013, 12(9):863-874. (this issue).
18. Marx A., Pfister F., Schalke B., Saruhan-Direskeneli G., Melms A., Ströbel P. The different roles of the thymus in the pathogenesis of the various myasthenia gravis subtypes. Autoimmun Rev 2013, 12(9):875-884. (this issue).
19. Gilhus N.E. Autoimmune myasthenia gravis. Expert Rev Neurother 2009, 9:351-358.
20. Vincent A. Unravelling the pathogenesis of myasthenia gravis. Nat Rev Immunol 2002, 2:797-804.
21. Romi F., Gilhus N.E., Aarli J.A. Myasthenia gravis: clinical, immunological, and therapeutic advances. Acta Neurol Scand 2005, 111:134-141.
22. Vincent A., Palace J., Hilton-Jones D. Myasthenia gravis. Lancet 2001, 357:2122-2128.
23. Scadding G.K., Vincent A., Newsom-Davis J., Henry K. Acetylcholine receptor antibody synthesis by thymic lymphocytes: correlation with thymic histology. Neurology 1981, 31:935-943.
24. Kuks J.B., Oosterhuis H.J., Limburg P.C., The T.H. Anti-acetylcholine receptor antibodies decrease after thymectomy in patients with myasthenia gravis. Clinical correlations. J Autoimmun 1991, 4:197-211.
25. Leprince C., Cohen-Kaminsky S., Berrih-Aknin S., Vernet-Der Garabedian B., Treton D., Galanaud P., et al. Thymic B cells from myasthenia gravis patients are activated B cells. Phenotypic and functional analysis. J Immunol 1990, 145:2115-2122.
26. Andrews P.I., Massey J.M., Sanders D.B. Acetylcholine receptor antibodies in juvenile myasthenia gravis. Neurology 1993, 43:977-982.
27. Andrews P.I., Massey J.M., Howard J.F., Sanders D.B. Race, sex, and puberty influence onset, severity, and outcome in juvenile myasthenia gravis. Neurology 1994, 44:1208-1214.
28. Chiu H.C., Vincent A., Newsom-Davis J., Hsieh K.H., Hung T. Myasthenia gravis: population differences in disease expression and acetylcholine receptor antibody titers between Chinese and Caucasians. Neurology 1987, 37:1854-1857.
29. Tindall R.S. Humoral immunity in myasthenia gravis: biochemical characterization of acquired antireceptor antibodies and clinical correlations. Ann Neurol 1981, 10:437-447.
30. Tindall R.S. Humoral immunity in myasthenia gravis: clinical correlations of anti-receptor antibody avidity and titer. Ann N Y Acad Sci 1981, 377:316-331.
31. Demaine A., Willcox N., Janer M., Welsh K., Newsom-Davis J. Immunoglobulin heavy chain gene associations in myasthenia gravis: new evidence for disease heterogeneity. J Neurol 1992, 239:53-56.
32. Oosterhuis H.J., Limburg P.C., Hummel-Tappel E., The T.H. Anti-acetylcholine receptor antibodies in myasthenia gravis. Part 2. Clinical and serological follow-up of individual patients. J Neurol Sci 1983, 58:371-385.
33. Rodgaard A., Nielsen F.C., Djurup R., Somnier F., Gammeltoft S. Acetylcholine receptor antibody in myasthenia gravis: predominance of IgG subclasses 1 and 3. Clin Exp Immunol 1987, 67:82-88.
34. Vincent A., Newsom-Davis J. Acetylcholine receptor antibody characteristics in myasthenia gravis. I. Patients with generalized myasthenia or disease restricted to ocular muscles. Clin Exp Immunol 1982, 49:257-265.
35. Lefvert A.K., Cuenoud S., Fulpius B.W. Binding properties and subclass distribution of anti-acetylcholine receptor antibodies in myasthenia gravis. J Neuroimmunol 1981, 1:125-135.
36. Lefvert A.K., Bergstrom K., Matell G., Osterman P.O., Pirskanen R. Determination of acetylcholine receptor antibody in myasthenia gravis: clinical usefulness and pathogenetic implications. J Neurol Neurosurg Psychiatry 1978, 41:394-403.
37. Lindstrom J.M., Seybold M.E., Lennon V.A., Whittingham S., Duane D.D. Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value. Neurology 1976, 26:1054-1059.
38. Vincent A., Newsom Davis J. Anti-acetylcholine receptor antibodies. J Neurol Neurosurg Psychiatry 1980, 43:590-600.
39. Takeo G., Motomura M., Mats H., Ohishi K., Yoshimura T., Tsujihata M., et al. Effect of myasthenic IgG on degradation of junctional acetylcholine receptor. Muscle Nerve 1993, 16:840-848.
40. Newsom-Davis J., Wilson S.G., Vincent A., Ward C.D. Long-term effects of repeated plasma exchange in myasthenia gravis. Lancet 1979, 1:464-468.
41. Newsom-Davis J., Vincent A. Combined plasma exchange and immunosuppression in myasthenia gravis. Lancet 1979, 2:688.
42. Janssen S.P., Phernambucq M., Martinez-Martinez P., De Baets M.H., Losen M. Immunosuppression of experimental autoimmune myasthenia gravis by mycophenolate mofetil. J Neuroimmunol 2008, 201-202:111-120.
43. Drachman D.B., Adams R.N., Josifek L.F., Self S.G. Functional activities of autoantibodies to acetylcholine receptors and the clinical severity of myasthenia gravis. N Engl J Med 1982, 307:769-775.
44. van der Neut Kolfschoten M., Schuurman J., Losen M., Bleeker W.K., Martinez-Martinez P., Vermeulen E., et al. Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange. Science 2007, 317:1554-1557.
45. Engel A.G., Lambert E.H., Howard F.M. Immune complexes (IgG and C3) at the motor end-plate in myasthenia gravis: ultrastructural and light microscopic localization and electrophysiologic correlations. Mayo Clin Proc 1977, 52:267-280.
46. Chamberlain-Banoub J., Neal J.W., Mizuno M., Harris C.L., Morgan B.P. Complement membrane attack is required for endplate damage and clinical disease in passive experimental myasthenia gravis in Lewis rats. Clin Exp Immunol 2006, 146:278-286.
47. Loutrari H., Kokla A., Tzartos S.J. Passive transfer of experimental myasthenia gravis via antigenic modulation of acetylcholine receptor. Eur J Immunol 1992, 22:2449-2452.
48. Losen M., Martinez-Martinez P., Phernambucq M., Schuurman J., Parren P.W., De Baets M.H. Treatment of myasthenia gravis by preventing acetylcholine receptor modulation. Ann N Y Acad Sci 2008, 1132:174-179.
49. Heinemann S., Bevan S., Kullberg R., Lindstrom J., Rice J. Modulation of acetylcholine receptor by antibody against the receptor. Proc Natl Acad Sci U S A 1977, 74:3090-3094.
50. Drachman D.B., Angus C.W., Adams R.N., Michelson J.D., Hoffman G.J. Myasthenic antibodies cross-link acetylcholine receptors to accelerate degradation. N Engl J Med 1978, 298:1116-1122.
51. Gomez C.M., Richman D.P. Anti-acetylcholine receptor antibodies directed against the alpha-bungarotoxin binding site induce a unique form of experimental myasthenia. Proc Natl Acad Sci U S A 1983, 80:4089-4093.
52. Almon R.R., Andrew C.G., Appel S.H. Serum globulin in myasthenia gravis: inhibition of alpha-bungarotoxin binding to acetylcholine receptors. Science 1974, 186:55-57.
53. Vernet-der Garabedian B., Morel E., Bach J.F. Heterogeneity of antibodies directed against the alpha-bungarotoxin binding site on human acetylcholine receptor and severity of myasthenia gravis. J Neuroimmunol 1986, 12:65-74.
54. Whiting P.J., Vincent A., Newsom-Davis J. Acetylcholine receptor antibody characteristics in myasthenia gravis. Fractionation of alpha-bungarotoxin binding site antibodies and their relationship to IgG subclass. J Neuroimmunol 1983, 5:1-9.
55. Hara H., Hayashi K., Ohta K., Itoh N., Nishitani H., Ohta M. Detection and characterization of blocking-type anti-acetylcholine receptor antibodies in sera from patients with myasthenia gravis. Clin Chem 1993, 39:2053-2057.
56. Lang B., Richardson G., Rees J., Vincent A., Newsom-Davis J. Plasma from myasthenia gravis patients reduces acetylcholine receptor agonist-induced Na+flux into TE671 cell line. J Neuroimmunol 1988, 19:141-148.
57. Wintzen A.R., Plomp J.J., Molenaar P.C., van Dijk J.G., van Kempen G.T., Vos R.M., et al. Acquired slow-channel syndrome: a form of myasthenia gravis with prolonged open time of the acetylcholine receptor channel. Ann Neurol 1998, 44:657-664.
58. Martinez-Martinez P., Losen M., Duimel H., Frederik P., Spaans F., Molenaar P., et al. Overexpression of rapsyn in rat muscle increases acetylcholine receptor levels in chronic experimental autoimmune myasthenia gravis. Am J Pathol 2007, 170:644-657.
59. Ito H., Yoshimura T., Satoh A., Takino H., Tsujihata M., Nagataki S. Immunohistochemical study of utrophin and dystrophin at the motor end-plate in myasthenia gravis. Acta Neuropathol 1996, 92:14-18.
60. Slater C.R., Young C., Wood S.J., Bewick G.S., Anderson L.V., Baxter P., et al. Utrophin abundance is reduced at neuromuscular junctions of patients with both inherited and acquired acetylcholine receptor deficiencies. Brain 1997, 120(Pt 9):1513-1531.
61. Losen M., Stassen M.H., Martinez-Martinez P., Machiels B.M., Duimel H., Frederik P., et al. Increased expression of rapsyn in muscles prevents acetylcholine receptor loss in experimental autoimmune myasthenia gravis. Brain 2005, 128:2327-2337.
62. Martinez-Martinez P., Phernambucq M., Steinbusch L., Schaeffer L., Berrih-Aknin S., Duimel H., et al. Silencing rapsyn in vivo decreases acetylcholine receptors and augments sodium channels and secondary postsynaptic membrane folding. Neurobiol Dis 2009, 35:14-23.
63. De Baets M., Stassen M., Losen M., Zhang X., Machiels B. Immunoregulation in experimental autoimmune myasthenia gravis - about T cells, antibodies, and endplates. Ann N Y Acad Sci 2003, 998:308-317.
64. Guyon T., Levasseur P., Truffault F., Cottin C., Gaud C., Berrih-Aknin S. Regulation of acetylcholine receptor alpha subunit variants in human myasthenia gravis. Quantification of steady-state levels of messenger RNA in muscle biopsy using the polymerase chain reaction. J Clin Invest 1994, 94:16-24.
65. Moulian N., Wakkach A., Guyon T., Poea S., Aissaoui A., Levasseur P., et al. Respective role of thymus and muscle in autoimmune myasthenia gravis. Ann N Y Acad Sci 1998, 841:397-406.
66. Ito Y., Miledi R., Molenaar P.C., Vincent A., Polak R.L., van Gelder M., et al. Acetylcholine in human muscle. Proc R Soc Lond B Biol Sci 1976, 192:475-480.
67. Molenaar P.C., Newsom-Davis J., Polak R.L., Vincent A. Choline acetyltransferase in skeletal muscle from patients with myasthenia gravis. J Neurochem 1981, 37:1081-1088.
68. Molenaar P.C., Polak R.L., Miledi R., Alema S., Vincent A., Newsom-Davis J. Acetylcholine in intercostal muscle from myasthenia gravis patients and in rat diaphragm after blockade of acetylcholine receptors. Prog Brain Res 1979, 49:449-458.
69. Cull-Candy S.G., Miledi R., Trautmann A., Uchitel O.D. On the release of transmitter at normal, myasthenia gravis and myasthenic syndrome affected human end-plates. J Physiol 1980, 299:621-638.
70. Plomp J.J., Van Kempen G.T., De Baets M.B., Graus Y.M., Kuks J.B., Molenaar P.C. Acetylcholine release in myasthenia gravis: regulation at single end-plate level. Ann Neurol 1995, 37:627-636.
71. Miledi R., Molenaar P.C., Polak R.L. Alpha-Bungarotoxin enhances transmitter "released" at the neuromuscular junction. Nature 1978, 272:641-643.
72. Masuda T., Motomura M., Utsugisawa K., Nagane Y., Nakata R., Tokuda M., et al. Antibodies against the main immunogenic region of the acetylcholine receptor correlate with disease severity in myasthenia gravis. J Neurol Neurosurg Psychiatry 2012, 83:935-940.
73. Luo J., Taylor P., Losen M., de Baets M.H., Shelton G.D., Lindstrom J. Main immunogenic region structure promotes binding of conformation-dependent myasthenia gravis autoantibodies, nicotinic acetylcholine receptor conformation maturation, and agonist sensitivity. J Neurosci 2009, 29:13898-13908.
74. Vrolix K., Fraussen J., Molenaar P.C., Losen M., Somers V., Stinissen P., et al. The auto-antigen repertoire in myasthenia gravis. Autoimmunity 2010, 43:380-400.
75. Marx A., Willcox N., Leite M.I., Chuang W.Y., Schalke B., Nix W., et al. Thymoma and paraneoplastic myasthenia gravis. Autoimmunity 2010, 43:413-427.
76. Mossman S., Vincent A., Newsom-Davis J. Myasthenia gravis without acetylcholine-receptor antibody: a distinct disease entity. Lancet 1986, 1:116-119.
77. Burges J., Vincent A., Molenaar P.C., Newsom-Davis J., Peers C., Wray D. Passive transfer of seronegative myasthenia gravis to mice. Muscle Nerve 1994, 17:1393-1400.
78. Vincent A., Leite M.I., Farrugia M.E., Jacob S., Viegas S., Shiraishi H., et al. Myasthenia gravis seronegative for acetylcholine receptor antibodies. Ann N Y Acad Sci 2008, 1132:84-92.
79. Hoch W., McConville J., Helms S., Newsom-Davis J., Melms A., Vincent A. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med 2001, 7:365-368.
80. Leite M.I., Jacob S., Viegas S., Cossins J., Clover L., Morgan B.P., et al. IgG1 antibodies to acetylcholine receptors in 'seronegative' myasthenia gravis. Brain 2008, 131:1940-1952.
81. Higuchi O., Hamuro J., Motomura M., Yamanashi Y. Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis. Ann Neurol 2011, 69:418-422.
82. Pevzner A., Schoser B., Peters K., Cosma N.C., Karakatsani A., Schalke B., et al. Anti-LRP4 autoantibodies in AChR- and MuSK-antibody-negative myasthenia gravis. J Neurol 2012, 259:427-435.
83. Zhang B., Tzartos J.S., Belimezi M., Ragheb S., Bealmear B., Lewis R.A., et al. Autoantibodies to lipoprotein-related protein 4 in patients with double-seronegative myasthenia gravis. Arch Neurol 2012, 69:445-451.
84. Lavrnic D., Losen M., Vujic A., De Baets M., Hajdukovic L.J., Stojanovic V., et al. The features of myasthenia gravis with autoantibodies to MuSK. J Neurol Neurosurg Psychiatry 2005, 76:1099-1102.
85. Evoli A., Tonali P.A., Padua L., Monaco M.L., Scuderi F., Batocchi A.P., et al. Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis. Brain 2003, 126:2304-2311.
86. Guptill J.T., Sanders D.B., Evoli A. Anti-MuSK antibody myasthenia gravis: clinical findings and response to treatment in two large cohorts. Muscle Nerve 2011, 44:36-40.
87. Hatanaka Y., Hemmi S., Morgan M.B., Scheufele M.L., Claussen G.C., Wolfe G.I., et al. Nonresponsiveness to anticholinesterase agents in patients with MuSK-antibody-positive MG. Neurology 2005, 65:1508-1509.
88. Diaz-Manera J., Martinez-Hernandez E., Querol L., Klooster R., Rojas-Garcia R., Suarez-Calvet X., et al. Long-lasting treatment effect of rituximab in MuSK myasthenia. Neurology 2012, 78:189-193.
89. Horvath B., Huizinga J., Pas H.H., Mulder A.B., Jonkman M.F. Low-dose rituximab is effective in pemphigus. Br J Dermatol 2012, 166:405-412.
90. Bhol K., Natarajan K., Nagarwalla N., Mohimen A., Aoki V., Ahmed A.R. Correlation of peptide specificity and IgG subclass with pathogenic and nonpathogenic autoantibodies in pemphigus vulgaris: a model for autoimmunity. Proc Natl Acad Sci U S A 1995, 92:5239-5243.
91. Leite M.I., Strobel P., Jones M., Micklem K., Moritz R., Gold R., et al. Fewer thymic changes in MuSK antibody-positive than in MuSK antibody-negative MG. Ann Neurol 2005, 57:444-448.
92. Bartoccioni E., Scuderi F., Augugliaro A., Chiatamone Ranieri S., Sauchelli D., Alboino P., et al. HLA class II allele analysis in MuSK-positive myasthenia gravis suggests a role for DQ5. Neurology 2009, 72:195-197.
93. Niks E.H., Kuks J.B., Roep B.O., Haasnoot G.W., Verduijn W., Ballieux B.E., et al. Strong association of MuSK antibody-positive myasthenia gravis and HLA-DR14-DQ5. Neurology 2006, 66:1772-1774.
94. Niks E.H., van Leeuwen Y., Leite M.I., Dekker F.W., Wintzen A.R., Wirtz P.W., et al. Clinical fluctuations in MuSK myasthenia gravis are related to antigen-specific IgG4 instead of IgG1. J Neuroimmunol 2008, 195:151-156.
95. Aalberse R.C., Stapel S.O., Schuurman J., Rispens T. Immunoglobulin G4: an odd antibody. Clin Exp Allergy 2009, 39:469-477.
96. Schroeder H.W., Cavacini L. Structure and function of immunoglobulins. J Allergy Clin Immunol 2010, 125:S41-S52.
97. Daha N.A., Banda N.K., Roos A., Beurskens F.J., Bakker J.M., Daha M.R., et al. Complement activation by (auto-) antibodies. Mol Immunol 2011, 48:1656-1665.
98. Aalberse R.C., Schuurman J. IgG4 breaking the rules. Immunology 2002, 105:9-19.
99. Sitaru C., Mihai S., Zillikens D. The relevance of the IgG subclass of autoantibodies for blister induction in autoimmune bullous skin diseases. Arch Dermatol Res 2007, 299:1-8.
100. Beck L.H., Bonegio R.G., Lambeau G., Beck D.M., Powell D.W., Cummins T.D., et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med 2009, 361:11-21.
101. Ferrari S., Mudde G.C., Rieger M., Veyradier A., Kremer Hovinga J.A., Scheiflinger F. IgG subclass distribution of anti-ADAMTS13 antibodies in patients with acquired thrombotic thrombocytopenic purpura. J Thromb Haemost 2009, 7:1703-1710.
102. Rock B., Martins C.R., Theofilopoulos A.N., Balderas R.S., Anhalt G.J., Labib R.S., et al. The pathogenic effect of IgG4 autoantibodies in endemic pemphigus foliaceus (fogo selvagem). N Engl J Med 1989, 320:1463-1469.
103. Lindstrom J. Is "seronegative" MG explained by autoantibodies to MuSK?. Neurology 2004, 62:1920-1921.
104. Selcen D., Fukuda T., Shen X.M., Engel A.G. Are MuSK antibodies the primary cause of myasthenic symptoms?. Neurology 2004, 62:1945-1950.
105. Shiraishi H., Motomura M., Yoshimura T., Fukudome T., Fukuda T., Nakao Y., et al. Acetylcholine receptors loss and postsynaptic damage in MuSK antibody-positive myasthenia gravis. Ann Neurol 2005, 57:289-293.
106. Cole R.N., Reddel S.W., Gervasio O.L., Phillips W.D. Anti-MuSK patient antibodies disrupt the mouse neuromuscular junction. Ann Neurol 2008, 63:782-789.
107. ter Beek W.P., Martinez-Martinez P., Losen M., de Baets M.H., Wintzen A.R., Verschuuren J.J., et al. The effect of plasma from muscle-specific tyrosine kinase myasthenia patients on regenerating endplates. Am J Pathol 2009, 175:1536-1544.
108. Cole R.N., Ghazanfari N., Ngo S.T., Gervasio O.L., Reddel S.W., Phillips W.D. Patient autoantibodies deplete postsynaptic muscle-specific kinase leading to disassembly of the ACh receptor scaffold and myasthenia gravis in mice. J Physiol 2010, 588:3217-3229.
109. Kawakami Y., Ito M., Hirayama M., Sahashi K., Ohkawara B., Masuda A., et al. Anti-MuSK autoantibodies block binding of collagen Q to MuSK. Neurology 2011, 77:1819-1826.
110. Klooster R., Plomp J.J., Huijbers M.G., Niks E.H., Straasheijm K.R., Detmers F.J., et al. Muscle-specific kinase myasthenia gravis IgG4 autoantibodies cause severe neuromuscular junction dysfunction in mice. Brain 2012, 135:1081-1101.
111. Viegas S., Jacobson L., Waters P., Cossins J., Jacob S., Leite M.I., et al. Passive and active immunization models of MuSK-Ab positive myasthenia: electrophysiological evidence for pre and postsynaptic defects. Exp Neurol 2012, 234:506-512.
112. Morsch M., Reddel S.W., Ghazanfari N., Toyka K.V., Phillips W.D. Muscle specific kinase autoantibodies cause synaptic failure through progressive wastage of postsynaptic acetylcholine receptors. Exp Neurol 2012, 237:286-295.
113. Mori S., Kubo S., Akiyoshi T., Yamada S., Miyazaki T., Hotta H., et al. Antibodies against muscle-specific kinase impair both presynaptic and postsynaptic functions in a murine model of myasthenia gravis. Am J Pathol 2012, 180:798-810.
114. Kim N., Stiegler A.L., Cameron T.O., Hallock P.T., Gomez A.M., Huang J.H., et al. Lrp4 is a receptor for Agrin and forms a complex with MuSK. Cell 2008, 135:334-342.
115. Yumoto N., Kim N., Burden S.J. Lrp4 is a retrograde signal for presynaptic differentiation at neuromuscular synapses. Nature 2012, 489:438-442.
116. Kummer T.T., Misgeld T., Sanes J.R. Assembly of the postsynaptic membrane at the neuromuscular junction: paradigm lost. Curr Opin Neurobiol 2006, 16:74-82.
117. Huze C., Bauche S., Richard P., Chevessier F., Goillot E., Gaudon K., et al. Identification of an agrin mutation that causes congenital myasthenia and affects synapse function. Am J Hum Genet 2009, 85:155-167.
118. Gautam M., Noakes P.G., Moscoso L., Rupp F., Scheller R.H., Merlie J.P., et al. Defective neuromuscular synaptogenesis in agrin-deficient mutant mice. Cell 1996, 85:525-535.